Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03283137
Title Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of Chicago

chronic lymphocytic leukemia

non-Hodgkin lymphoma


Pembrolizumab + Umbralisib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.